Vivani's Losses Widen Amid Increased R&D for GLP-1 Implants

TL;DR

**VANI is burning cash fast, but their GLP-1 implant tech could be a game-changer if they can fund it through trials.**

AI Summary

Vivani Medical, Inc. (VANI) reported a net loss of $6.53 million for the three months ended September 30, 2025, an increase from $6.04 million in the same period of 2024. For the nine months ended September 30, 2025, the net loss widened to $19.98 million from $17.44 million in 2024. Research and development expenses increased to $13.50 million for the nine months ended September 30, 2025, up from $11.44 million in the prior year, reflecting increased clinical trial activity. General and administrative expenses also rose to $7.25 million from $6.78 million. The company's cash and cash equivalents significantly decreased from $18.35 million at December 31, 2024, to $2.63 million at September 30, 2025, indicating substantial cash burn. Vivani is advancing its NanoPortal technology for ultra long-acting subdermal drug implants, with lead program NPM-139 (semaglutide implant) showing promising preclinical weight loss data of approximately 20% in rats. The LIBERATE-1 clinical trial for NPM-115 (exenatide implant) in obese and overweight individuals demonstrated a positive safety and tolerability profile, paving the way for future semaglutide implant development.

Why It Matters

Vivani's widening net loss and significant cash burn are critical for investors, signaling a need for further capital raises to fund its ambitious clinical pipeline. The successful LIBERATE-1 trial and promising preclinical data for NPM-139 position Vivani as a potential disruptor in the chronic weight management and diabetes markets, currently dominated by injectables like Wegovy and Ozempic. If Vivani's NanoPortal technology can deliver on its promise of ultra long-acting, adherence-guaranteeing implants, it could capture significant market share by addressing a major pain point for patients and healthcare providers. However, the competitive landscape is fierce, with major pharmaceutical companies investing heavily in GLP-1 therapies, making Vivani's path to commercialization challenging.

Risk Assessment

Risk Level: high — Vivani's cash and cash equivalents plummeted from $18.35 million at December 31, 2024, to $2.63 million at September 30, 2025, representing an 85.7% decrease. The company also reported a net loss of $19.98 million for the nine months ended September 30, 2025, and total stockholders' equity of only $1.31 million, indicating a precarious financial position and high reliance on future financing to continue operations.

Analyst Insight

Investors should monitor Vivani's upcoming financing activities closely, as the current cash reserves are insufficient for sustained operations. While the clinical progress is encouraging, the high burn rate and significant accumulated deficit of $141.90 million suggest extreme caution. Consider this a highly speculative investment, contingent on successful clinical outcomes and substantial future capital raises.

Financial Highlights

debt To Equity

Not Disclosed

revenue

Not Disclosed

operating Margin

Not Disclosed

total Assets

Not Disclosed

total Debt

Not Disclosed

net Income

-$19.98M

eps

Not Disclosed

gross Margin

Not Disclosed

cash Position

$2.63M

revenue Growth

Not Disclosed

Key Numbers

• $2.63M — Cash and cash equivalents (Decreased from $18.35M at Dec 31, 2024, indicating significant cash burn.)
• $19.98M — Net loss for nine months (Widened from $17.44M in the prior year, reflecting increased operating expenses.)
• $13.50M — Research and development expenses (Increased from $11.44M for the nine months, driven by clinical trial advancements.)
• 20% — Weight loss in preclinical study (Achieved by NPM-139 (semaglutide implant) in rats, maintained for over seven months.)
• 72,952,235 — Common shares outstanding (As of November 12, 2025.)
• $1.31M — Total Stockholders' Equity (Significantly reduced from $17.61M at December 31, 2024, highlighting financial strain.)

Key Players & Entities

• Vivani Medical, Inc. (company) — registrant
• NPM-139 (product) — lead semaglutide implant program
• NPM-115 (product) — exenatide implant in LIBERATE-1 trial
• FDA (regulator) — cleared IND for NPM-119
• Okava Pharmaceuticals, Inc. (company) — animal health partner
• Cortigent, Inc. (company) — wholly owned subsidiary for neurostimulation technology
• Second Sight Medical Products, Inc. (company) — legacy company merged with NPM
• Nano Precision Medical, Inc. (company) — merged with Second Sight to form Vivani

FAQ

Risk Factors

• Substantial cash burn and need for future financing [high — financial]: The company's cash and cash equivalents decreased from $18.35 million at December 31, 2024, to $2.63 million at September 30, 2025. This significant burn rate necessitates future capital raises, which may be dilutive to existing shareholders or subject to market conditions.
• Clinical trial delays and regulatory approval uncertainty [high — regulatory]: Vivani's success hinges on the successful completion of clinical trials and subsequent regulatory approvals for its NanoPortal technology. Delays or failures in trials, such as for NPM-139 or NPM-115, could significantly impact the company's timeline and financial viability.
• Dependence on key personnel and technology development [medium — operational]: The company relies on its key scientific and management personnel for the development and commercialization of its proprietary NanoPortal technology. Any loss of key personnel or unforeseen technical challenges in developing the drug delivery system could hinder progress.
• Competition in the obesity and diabetes drug market [medium — market]: The market for obesity and diabetes treatments is highly competitive, with established players and emerging technologies. Vivani's NanoPortal technology must demonstrate significant advantages in efficacy, safety, or convenience to gain market share.
• Increasing net losses and operating expenses [high — financial]: The company reported a net loss of $19.98 million for the nine months ended September 30, 2025, an increase from $17.44 million in the prior year. This widening loss, driven by increased R&D and G&A expenses, highlights the ongoing investment required before potential revenue generation.

Industry Context

Vivani operates in the highly competitive pharmaceutical and biotechnology sector, specifically targeting the growing markets for obesity and chronic disease management. Key industry trends include the development of novel drug delivery systems offering improved patient compliance and sustained therapeutic effects, as well as advancements in GLP-1 receptor agonists for weight loss and diabetes. The company faces competition from established pharmaceutical giants and other biotech firms developing similar long-acting injectable or implantable therapies.

Regulatory Implications

Vivani's product development is subject to stringent regulatory oversight by agencies like the FDA. Successful navigation of clinical trials (e.g., LIBERATE-1) and adherence to Good Manufacturing Practices (GMP) are critical for obtaining marketing approval. Any delays, adverse findings in trials, or manufacturing issues could significantly impede market entry and revenue generation.

What Investors Should Do

1. Monitor cash burn and future financing activities
2. Track progress of clinical trials for NPM-139 and NPM-115
3. Assess competitive landscape and differentiation of NanoPortal technology

Key Dates

• 2025-09-30: End of third quarter 2025 — Reporting period for the 10-Q, showing a net loss of $6.53 million for the quarter and a significant decrease in cash to $2.63 million.
• 2024-12-31: End of fiscal year 2024 — Starting point for cash balance comparison, with $18.35 million in cash and cash equivalents.

Glossary

NanoPortal technology

Vivani Medical's proprietary drug delivery system designed for ultra long-acting subdermal implants. (This is the core technology platform for all of Vivani's product candidates, central to the company's value proposition.)

NPM-139

Vivani's lead program utilizing the NanoPortal technology, intended as a semaglutide implant for weight loss. (Shows promising preclinical data, indicating potential for future development and market entry in the weight loss segment.)

NPM-115

A NanoPortal technology implant utilizing exenatide, tested in the LIBERATE-1 clinical trial. (Demonstrated a positive safety and tolerability profile, supporting the platform's viability and paving the way for further development, including semaglutide implants.)

Subdermal implant

A small device surgically placed under the skin to deliver medication over an extended period. (The delivery mechanism for Vivani's drug candidates, offering potential advantages in patient compliance and sustained drug release.)

Cash burn

The rate at which a company spends its available cash reserves, typically used for companies that are not yet profitable. (Highlights the rapid depletion of Vivani's cash reserves, indicating a significant need for future funding.)

Year-Over-Year Comparison

The nine months ended September 30, 2025, show a widening net loss to $19.98 million from $17.44 million in the prior year, driven by increased R&D and G&A expenses. Most critically, cash and cash equivalents have plummeted from $18.35 million at the end of 2024 to $2.63 million as of September 30, 2025, indicating a substantial increase in cash burn and a heightened need for future financing.

Key Financial Figures

• $0.0001 — h Registered Common Stock , par value $0.0001 per share VANI The NASDAQ Capital M

Filing Documents

• vani-20250930.htm (10-Q) — 1481KB
• ex311_1.htm (EX-31.1) — 18KB
• ex312_2.htm (EX-31.2) — 12KB
• ex321_3.htm (EX-32.1) — 12KB
• 0001753926-25-001770.txt ( ) — 7904KB
• vani-20250930_def.xml (EX-101.DEF) — 324KB
• vani-20250930_pre.xml (EX-101.PRE) — 469KB
• vani-20250930_cal.xml (EX-101.CAL) — 56KB
• vani-20250930_lab.xml (EX-101.LAB) — 747KB
• vani-20250930.xsd (EX-101.SCH) — 59KB
• vani-20250930_htm.xml (XML) — 1262KB

Financial Statements (Unaudited)

Financial Statements (Unaudited) 2 Condensed Consolidated Balance Sheets as of September 30, 2025 and December 31, 2024 2 Condensed Consolidated Statements of Operations for the three and nine months ended September 30, 2025 and 2024 3 Condensed Consolidated Statements of Comprehensive Loss for the three and nine months ended September 30, 2025 and 2024 4 Condensed Consolidated Statements of Stockholders' Equity for each three month period ended during the nine months ended September 30, 2025 and 2024 5 Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2025 and 2024 6 Notes to Condensed Consolidated Financial Statements 7 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 25 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 32 Item 4.

Controls and Procedures

Controls and Procedures 32 PART II OTHER INFORMATION 33 Item 1.

Legal Proceedings

Legal Proceedings 33 Item 1A.

Risk Factors

Risk Factors 34 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 37 Item 3. Defaults upon Senior Securities 37 Item 4. Mine Safety Disclosures 37 Item 5. Other Information 37 Item 6. Exhibits 38

SIGNATURES

SIGNATURES 39 1 PART I. FINANCIAL STATEMENTS Item 1. Financial Statements VIVANI MEDICAL, INC. AND SUBSIDIARIES Condensed Consolidated Balance Sheets (Unaudited) (In thousands, except per share data) September 30, December 31, 2025 2024 ASSETS CURRENT ASSETS: Cash and cash equivalents $ 2,628 $ 18,352 R&D tax credit incentive receivable 664 253 Prepaid expenses and other current assets 883 1,837 Total current assets 4,175 20,442 Property and equipment, net 2,726 1,693 Operating lease right-of-use assets, net 16,784 17,957 Restricted cash 1,338 1,338 Deposits and other assets 23 131 TOTAL ASSETS $ 25,046 $ 41,561 LIABILITIES AND STOCKHOLDERS' EQUITY CURRENT LIABILITIES: Accounts payable $ 1,434 $ 817 Accrued expenses 1,978 1,803 Litigation accrual 1,675 1,675 Accrued compensation expense 357 343 Lease liability, current portion 1,386 1,348 Total current liabilities 6,830 5,986 Lease liability, noncurrent portion 16,907 17,965 TOTAL LIABILITIES 23,737 23,951 Commitments and contingencies (Note 12) Stockholders' equity: Preferred stock, par value $ 0.0001 per share; 10,000 shares authorized; none outstanding - - Common stock, par value $ 0.0001 per share; 300,000 shares authorized; shares issued and outstanding: 61,511 and 59,235 at September 30, 2025 and December 31, 2024 , respectively 6 6 Additional paid-in capital 143,062 139,480 Accumulated other comprehensive income 141 48 Accumulated deficit ( 141,900 ) ( 121,924 ) TOTAL STOCKHOLDERS' EQUITY 1,309 17,610 TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY $ 25,046 $ 41,561 The accompanying notes are an integral part of these condensed consolidated financial statements. 2 VIVANI MEDICAL, INC. AND SUBSIDIARIES Condensed Consolidated Statements of Operations (Unaudited) (In thousands, except per share data) Three Months Ende

View Full Filing

View this 10-Q filing on SEC EDGAR